Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.PMID:38458013 | DOI:10.1016/j.biopha.2024.116366

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 8, 2024 Category: Drugs & Pharmacology Authors: Renshun Dong Tianci Wang Wei Dong He Zhu Qiumeng Liu Huifang Liang Xiaoping Chen Bixiang Zhang Xuewu Zhang Source Type: research